INTRODUCTION: Several recent retrospective analyses have shown conflicting correlation of doses of radiotherapy (RT) to SVZ with survival in patients with glioblastoma (GBM). We present the results of a prospective study evaluating RT doses received by SVZ in patients diagnosed with newly-diagnosed GBM and their impact on survival. MATERIAL AND METHODS: Between 2012-2016, 100 patients with newly diagnosed GBM were accrued in this IRB approved prospective study. 80 patients who completed their adjuvant treatment form the study group for the present analysis. Patients underwent maximal safe surgical resection followed by adjuvant focal conformal RT to a dose of 59.4 Gy/33 fractions with standard concurrent temozolomide and 6-12 adjuvant temozolomide chemotherapy. We did not specifically consider SVZ during RT planning, which was done as per standard criteria of tumour bed+2-3 cms margin as CTV+5 mm margin as PTV. Tumours were divided into groups based on their spatial relationship to SVZ. Ipsilateral, contralateral, and bilateral SVZs were contoured on RT treatment plans by the use of co-registered MRI and CT scans. Multivariate Cox regression was used to examine the relationship between SVZ dose and progression-free survival (PFS) and overall survival (OS). PFS was measured by the RANO criteria and MR Spectroscopy and MR perfusion were used routinely. RESULTS: Median age of patients was 49 years (17-78) and median KPS was 80. GTR was achieved in 22 patients (27.5%), STR in 47 patients (58.7%) and biopsy in 11 patients (13.8%). Median PFS and OS of the entire cohort of 80 studied patients were 13.43 months and 15.4 months respectively. The grouping of SVZ showed 29 patients (36%) in group I, 14 patients (18%) in group II, 29 patients (36%) in group III, and 8 (%) patients in group IV, which however did not influence PFS and OS significantly. The mean and median doses received by the ipsilateral SVZ was 54.2 Gy and 59 Gy (0-60.99 Gy), for contralateral SVZ was 43.7 Gy and 47.84 Gy (0-60.88 Gy) and for combined SVZ was 48.8 Gy and 50.87 Gy (12.12-60.46), respectively. On multivariate analysis, patients who received <59 Gy to the ipsilateral SVZ had significantly better outcomes than patients who received > 59 Gy to the the ipsilateral SVZ both in terms of median PFS (20.5 vs. 9.7 months, p=0.016) and OS (20.6 vs. 13.3 months, p=0.026). Patients who received <47.85 Gy to the contralateral SVZ had significant longer median PFS than those who received >47.85 Gy (35 vs 10.9 months, p=0.014) but had no impact on OS. MGMT was done in 45 patients, 18 patients were methylated with median OS of 16.8 months. CONCLUSION: Our trial, probably the first prospective study correlating the relationship of SVZ dosimetry with survival in a reasonably large number of patients demonstrates an inverse correlation between the RT doses received by ipsilateral and contralateral SVZ with survival, and should set a benchmark to plan appropriate studies.
INTRODUCTION: Machine learning methods are integrated in clinical research studies due to their strong capability to discover parameters having a high information content and their predictive combined potential. Several studies have been developed using glioblastoma patient's imaging data. Many of them have focused on including large numbers of variables, mostly two-dimensional textural features and/or genomic data, regardless of their meaning or potential clinical relevance. MATERIALS AND METHODS: 193 glioblastoma patients were included in the study. Preoperative 3D magnetic resonance images were collected and semi-automatically segmented using an in-house software. After segmentation, a database of 90 parameters including geometrical and textural image-based measures together with patients' clinical data (including age, survival, type of treatment, etc.) was constructed. The criterion for including variables in the study was that they had either shown individual impact on survival in single or multivariate analyses or have a precise clinical or geometrical meaning. These variables were used to perform several machine learning experiments. In a first set of computational cross-validation experiments based on regression trees, those attributes showing the highest information measures were extracted. In the second phase, more sophisticated learning methods were employed in order to validate the potential of the previous variables predicting survival. Concretely support vector machines, neural networks and sparse grid methods were used. RESULTS: Variables showing high information measure in the first phase provided the best prediction results in the second phase. Specifically, patient age, Stupp regimen and a geometrical measure related with the irregularity of contrast-enhancing areas were the variables showing the highest information measure in the first stage. For the second phase, the combinations of patient age and Stupp regimen together with one tumor geometrical measure and one tumor heterogeneity feature reached the best quality prediction. CONCLUSIONS: Advanced machine learning methods identified the parameters with the highest information measure and survival predictive potential. The uninformed machine learning methods identified a novel feature measure with direct impact on survival. Used in combination with other previously known variables multi-indexes can be defined that can help in tumor characterization and prognosis prediction. Recent advances on the definition of those multi-indexes will be reported in the conference.
FUNDING: James S. Chemotherapies [temozolomide (TMZ), bevacizumab (BEV), irinotecan (IRI)] are commonly used drugs treating glioblastoma multiforme (GBM). The side effects from individual drug are well-known clinically and are manageable. Most of side effects are reversible after discounting the suspected drug(s). Combination chemotherapies either concurrently or in sequence are common in oncology practice. Most GBM patients received TMZ first followed by BEV with or without IRI. However, the side effects or permanent end-organs injuries of cumulative toxicity profiles are not well established. Whether these chemotherapies will lead to permanent end-organ damage by post-mortem pathological examination after long term use of either single drug or combination of two or three of the above listed chemotherapy drugs has never been studied in detail. In this study, 45 post-mortem pathological examination and some with electronic microscopic examinations are performed to study possible end-organ toxicity attributed to chemotherapies. Consent for autopsy were obtained from next of kin from each of the subjects. Postmortem organ specific studies including gross exam, H&E, immunohistochemistry study, electron microscopy (EM) (n=8) and immunofluorescence (IF). Autopsy cases include 35 GBMs, 6 brain metastatic cancers, 1 grade II and 2 grade III gliomas, 1 spinal glioma from UTHealth and Tufts medical center since 2007 to 2016. Twenty eight male and 17 female subjects were included with ages ranging from 20 to 79 years old (median 62 years old). Clinical toxicities and laboratory abnormalities were collected and correlated with autopsy results. At autopsy, there was no significant morphologic evidence of TMZ/BEV or TMZ/BEV/IRI-related injury in heart, lung, liver, adrenal glands, thyroid, pancreas, spleen, bladder or bone marrow which we did not know clinically. The cause of death in most patients was bronchopneumonia. Pulmonary embolism was confirmed in 4 cases with 2 case showing additional alveolar hemorrhage. One case had peritonitis with diverticular perforation diagnosed pre-mortem during BEV therapy. EM evaluation of renal glomerular ultrastructure reveal extensive postmortem autolytic change; however there was sufficient preservation to determine that podocyte foot processes were mostly preserved, but glomeruli had segmental to global subendothelial expansion by edematous, flocculent, matrix indicative of endothelial injury. IF examination showed no immune complex deposition. With exception of kidney, there is no significant end-organ damage found by standard postmortem pathological examinations including subjects with long term use of combination of TMZ, BEV and IRI therapies. In the kidney, the toxicity is mild to moderate endothelial injury which is consistent with thrombotic microangiopathy which may be the cause of proteinuria and hypertension seen clinically.
